Predictors of relapse in a prospective study of fluoxetine treatment of major depression

American Journal of Psychiatry

Volumn 163, Issue 9, 2006, Pages 1542-1548

  McGrath, Patrick J ^a   Stewart, Jonathan W ^b   Quitkin, Frederic M ^b   Chen, Ying ^b   Alpert, Jonathan E ^b   Nierenberg, Andrew A ^b   Fava, Maurizio ^b   Cheng, Jianfeng ^b   Petkova, Eva ^b  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; PLACEBO;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CHRONICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COVARIANCE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG SUBSTITUTION; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RISK FACTOR; SEX DIFFERENCE; SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL;

EID: 33749075174     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2006.163.9.1542     Document Type: Article

References (31)

1. Byrne S, Rothschild A: Loss of antidepressant efficacy during maintenance therapy: possible mechanisms and treatments. J Clin Psychiatry 1988; 59:279-288
2. Nierenberg A, Alpert J: Depressive breakthrough. Psychiatr Clin North Am 2000; 23:731-742
3. Montgomery SA, Dufour H, Brion S, Gailledreau J, Laqueille X, Ferry G, Moron P, Parant-Lucena N, Singer L, Danion JM, Beuzen J, Pierredon M: The prophylactic efficacy of fluoxetine in unipolar depression. Br J Psychiatry 1988; 153(suppl):69-76
4. Fava M, Kaji J: Continuation and maintenance treatment of major depressive disorder. Psychiatr Ann 1994; 42:281-290
5. Geddes J, Carney S, Davies C, Furukawa T, Kupfer D, Frank E, Goodwin G: Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003; 361:653-661
6. Prien R: Maintenance therapy, in Handbook of Affective Disorders. Edited by Payke E. London, Churchill Livingston, 1992, pp 840-848
7. Prien R, Kupfer D, Mansky P, Small J, Tuason V, Voss C: Drug therapy in the prevention of recurrences in unipolar and bipolar affective episodes. Arch Gen Psychiatry 1984; 41:1096-1104
8. Coppen A, Baldessarini R: Tolerance to therapeutic effects of antidepressants. Arch Gen Psychiatry 1985; 142:489-490
9. Rouillon F, Phillips R, Serruier D, Ansart E, Gerard J: Recurrence of unipolar depression and efficacy of maprotiline. Encephale 1989; 15:527-534
10. Frank E, Kupfer D, Perel J, Cornes C, Jarrett D, Mallinger A: Three year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990; 47:1093-1099
11. Doogan DP, Caillard V: Sertraline in the prevention of depression. Br J Psychiatry 1992; 160:217-222
12. Kupfer DJ, Frank E, Perel JM, Cornes C, Mallinger AG, Thase ME, McEachran AB, Grochocinski VJ: Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1992; 49:769-773
13. Montgomery SA, Dunbar G: Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression. Int Clin Psychopharmacol 1993; 8:189-195
14. Stewart JW, Quitkin FM, McGrath PJ, Amsterdam J, Fava M, Fawcett J, Reimherr F, Rosenbaum J, Beasley C, Roback P: Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry 1998; 55:334-343
15. Klerman GL, Cole JO: Clinical pharmacology of imipramine and related antidepressant compounds. Pharmacol Rev 1965; 17:101-141
16. Quitkin FM, Rabkin JG, Ross D, Stewart JW: Identification of true drug response to antidepressants: use of pattern analysis. Arch Gen Psychiatry 1984; 41:782-786
17. Fieve RR, Goodnick PJ, Peselow ED, Barouche F, Schlegel A: Pattern analysis of antidepressant response to fluoxetine. J Clin Psychiatry 1986; 47:560-562
18. Dunlop SR, Dornseif BE, Wernicke JF, Potvin JH: Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull 1990; 26:173-180
19. Nierenberg AA, Quitkin FM, Kremer C, Keller MB, Thase ME: Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 2004; 29:1012-1018
20. McGrath PJ, Stewart JW, Petkova E, Quitkin FM, Amsterdam JD, Fawcett J, Reimherr FW, Rosenbaum JF, Beasley CM Jr: Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry 2000; 67:518-524
21. First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders, Patient Edition (SCID-P), version 2. New York, New York State Psychiatric Institute, Biometrics Research, 1995
22. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
23. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology, revised ed. Rockville, Md, National Institute of Mental Health, 1976
24. Cox D, Oakes D: Analysis of Survival Data. London, Chapman & Hall, 1984
25. Lee E: Statistical Methods for Survival Data Analysis. New York, Wiley, 1992
26. Therneau T, Grambsch P, Fleming T: Martingale based residuals for survival models. Biometrika 1990; 77:147-160
27. Kornstein SG, Sloan DM, Thase ME: Gender-specific differences in depression and treatment response. Psychopharmacol Bull 2002; 36:99-112
28. Quitkin FM, Stewart JW, McGrath PJ, Taylor BP, Tisminetzky MS, Petkova E, Ma YG, Klein DF: Are there differences between women's and men's antidepressant responses? Am J Psychiatry 2002; 159:1848-1854
29. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, Arifuzzman AI, Houle S, Vaccarino FJ: Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 2001; 158:899-905
30. Judd LL, Paulus MJ, Schettler PJ, Akiskal HS, Endicott J, Leon AC, Maser JD, Mueller T, Solomon DA, Keller MB: Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157:1501-1504
31. Amsterdam JD, Fawcett J, Quitkin FM, Reimherr FW, Rosenbaum JF, Michelson D, Hornig-Rohan M, Beasley CM: Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997; 154:963-969